Implementation of MAPPS: An End-to-End Automation System for Enhanced Analytical Testing in CMC Process Development

The increasing demand for analytical testing in Chemistry, Manufacturing, and Controls process development requires innovative solutions to maintain quality while scaling throughput. This presentation describes the successful implementation of MAPPS (Multi-Analytical Purification Process Suite), a comprehensive end-to-end automation platform designed to address these challenges in analytical workflows.
MAPPS integrates both physical and digital automation components to create a seamless analytical testing environment. The system architecture encompasses automated sample handling, liquid handling robotics, analytical instrumentation integration, and sophisticated data management software. This approach eliminates manual intervention points that traditionally limit throughput and introduce variability.
MAPPS has delivered significant operational improvements. Throughput capacity has increased substantially, enabling faster screening cycles throughout process development phases. The system processes significantly more samples per full-time equivalent compared to traditional manual workflows, dramatically improving laboratory efficiency and resource utilization.
Critical to adoption was demonstrating analytical equivalence between automated and manual sample preparation methods. Comparative studies reveal that MAPPS maintains or improves data quality and precision relative to manual processes. Statistical analysis of key analytical parameters shows comparable accuracy with reduced variability, confirming that automation enhances rather than compromises analytical integrity.
The successful deployment of MAPPS demonstrates how strategic automation implementation can simultaneously address capacity constraints and quality requirements in CMC analytical laboratories. This approach provides a scalable model for laboratories seeking to enhance throughput while maintaining rigorous analytical standards, ultimately supporting accelerated drug development timelines.